title: Comparison the efficacy of second-line modified EOX (epirubicin, oxaliplatin, and capecitabine) and irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) regimens in metastatic gastric cancer patients that progressed on first-line modified docetaxel and cisplatin plus fluorouracil (DCF) regimen.
abstract: Gastric cancer is often diagnosed in advanced stage. Palliative chemotherapy or best supportive care is recommended for patients with metastatic gastric patients. In several clinical trials, palliative chemotherapy improved overall survival (OS) and progression-free survival (PFS), but the survival benefit of second-line chemotherapy was demonstrated in small cohort studies. The main aim of our study was to compare retrospectively the efficacy of second-line modified EOX (epirubicin, oxaliplatin and capecitabine) [mEOX] and irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) regimens in metastatic gastric cancer patients that progressed on first-line modified docetaxel-cisplatin-fluorouracil (DCF) regimen. Metastatic gastric cancer patients who progressed on modified DCF regimens were included. A total 105 patients were included to this study; 55 and 50 patients were treated with mEOX and FOLFIRI regimens, respectively. The clinicopathological and demographic characteristics of all patients were collected from the medical charts. Kaplan-Meier survival analysis was carried out for PFS and OS. The median follow-up of our study was 16 (4-85) months. In both groups, all of the patients were treated with first-line mDCF. Median cycle of second-line chemotherapy was 3 (1-8) and 3.5 (1-6) in EOX and FOLFIRI groups, respectively (P = 0.44). Overall response rate was observed in 34.6 % and 42.0 % of patients second-line chemotherapy in mEOX and FOLFIRI arms, respectively (P = 0.17). Median PFS was 5.5 and 6.3 months in mEOX and FOLFIRI arms, respectively (P = 0.98). Median OS was 6.9 and 7.0 months in mEOX and FOLFIRI arms, respectively, from the time of beginning second-line chemotherapy protocol (P = 0.89). As compared with FOLFIRI regimen, mEOX regimen was associated with less neutropenia, thrombocytopenia and anemia. Dose reduction and dose delay were significantly higher in FOLFIRI group compared to mEOX group (P < 0.001). In our trial, triplet regimens mEOX and FOLFIRI regimens have similar efficacy as second-line treatment for patients with metastatic gastric cancer. FOLFIRI regimen was associated with more hematological toxicity.
authors.affiliation: Department of Medical Oncology, Faculty of Medicine, Yıldırım Beyazıt University, 06800, Ankara, Turkey, masendur@yahoo.com.tr.
authors.forename: Mehmet Ali Nahit
authors.initials: MA
authors.lastname: Sendur
authors.forename: Nuriye
authors.initials: N
authors.lastname: Ozdemir
authors.forename: Tahsin
authors.initials: T
authors.lastname: Özatlı
authors.forename: Ozan
authors.initials: O
authors.lastname: Yazıcı
authors.forename: Sercan
authors.initials: S
authors.lastname: Aksoy
authors.forename: Ahmet Siyar
authors.initials: AS
authors.lastname: Ekinci
authors.forename: Doğan
authors.initials: D
authors.lastname: Yazılıtaş
authors.forename: Yusuf
authors.initials: Y
authors.lastname: Günaydın
authors.forename: Berna
authors.initials: B
authors.lastname: Oksuzoglu
authors.forename: Mustafa
authors.initials: M
authors.lastname: Benekli
authors.forename: Nurullah
authors.initials: N
authors.lastname: Zengin
mesh_terms: D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D002166:Camptothecin / Q000031:analogs & derivatives; D064147:Febrile Neutropenia; D005260:Female; D005472:Fluorouracil; D006801:Humans; D053208:Kaplan-Meier Estimate; D002955:Leucovorin; D008297:Male; D008875:Middle Aged; D012189:Retrospective Studies; D013274:Stomach Neoplasms / Q000188:drug therapy / Q000453:epidemiology / Q000473:pathology; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D002955:Leucovorin; D005472:Fluorouracil; D002166:Camptothecin
references.citation: Ann Oncol. 2013 Nov;24(11):2850-4
references.pmid: 23942775
references.citation: Semin Oncol. 2003 Jun;30(3 Suppl 7):3-14
references.pmid: 12840796
references.citation: J Clin Oncol. 2006 Jun 20;24(18):2903-9
references.pmid: 16782930
references.citation: J Natl Compr Canc Netw. 2013 May 1;11(5):531-46
references.pmid: 23667204
references.citation: Ann Oncol. 2008 Nov;19(11):1882-7
references.pmid: 18669868
references.citation: Anticancer Drugs. 2008 Nov;19(10):1013-8
references.pmid: 18827567
references.citation: Am J Clin Oncol. 2004 Oct;27(5):477-80
references.pmid: 15596914
references.citation: N Engl J Med. 2008 Jan 3;358(1):36-46
references.pmid: 18172173
references.citation: Mol Clin Oncol. 2013 Jul;1(4):749-752
references.pmid: 24649240
references.citation: Chin Med J (Engl). 2011 Oct;124(19):2997-3002
references.pmid: 22040543
references.citation: J Clin Oncol. 2008 Mar 20;26(9):1435-42
references.pmid: 18349393
references.citation: Oncology (Williston Park). 2002 May;16(5 Suppl 5):16-8
references.pmid: 12109800
references.citation: J Clin Oncol. 1997 Jan;15(1):261-7
references.pmid: 8996151
references.citation: Lancet. 2010 Aug 28;376(9742):687-97
references.pmid: 20728210
references.citation: J Cancer Res Clin Oncol. 2010 Apr;136(4):503-10
references.pmid: 19777259
references.citation: Eur J Cancer. 2011 Oct;47(15):2306-14
references.pmid: 21742485
references.citation: Ann Oncol. 1997 Feb;8(2):163-8
references.pmid: 9093725
references.citation: Ann Oncol. 2013 Oct;24 Suppl 6:vi57-63
references.pmid: 24078663
references.citation: Anticancer Drugs. 2005 Jul;16(6):621-5
references.pmid: 15930889
references.citation: Jpn J Clin Oncol. 1990 Jun;20(2):169-76
references.pmid: 2370696
references.citation: Cancer. 1993 Jul 1;72(1):37-41
references.pmid: 8508427
references.citation: J Exp Clin Cancer Res. 2013 Sep 17;32:67
references.pmid: 24330513
references.citation: Eur J Cancer. 2014 May;50(8):1437-45
references.pmid: 24560487
references.citation: Gan To Kagaku Ryoho. 1994 Jun;21(7):1033-8
references.pmid: 8210254
references.citation: Transl Oncol. 2014 Apr;7(2):277-83
references.pmid: 24704535
references.citation: Med Oncol. 2010 Sep;27(3):680-4
references.pmid: 19633962
references.citation: J Clin Oncol. 2012 May 1;30(13):1513-8
references.pmid: 22412140
references.citation: Br J Cancer. 1995 Mar;71(3):587-91
references.pmid: 7533517
references.citation: J Chemother. 2012 Aug;24(4):217-20
references.pmid: 23040686
references.citation: Lancet Oncol. 2008 Mar;9(3):215-21
references.pmid: 18282805
references.citation: J Clin Oncol. 2006 Nov 1;24(31):4991-7
references.pmid: 17075117
references.citation: CA Cancer J Clin. 2014 Jan-Feb;64(1):9-29
references.pmid: 24399786
references.citation: Jpn J Clin Oncol. 2004 Jan;34(1):8-13
references.pmid: 15020657